2025년 08월 15일 금요일
 
 
  현재위치 > 뉴스지닷컴 > Science & Technology

랜섬웨어부터 돼지도살까지... 노련해진 사기행각

 

정치

 

경제

 

사회

 

생활

 

문화

 

국제

 

과학기술

 

연예

 

스포츠

 

자동차

 

부동산

 

경영

 

영업

 

미디어

 

신상품

 

교육

 

학회

 

신간

 

공지사항

 

칼럼

 

캠페인
한살림 ‘우리는 한쌀림’ 쌀 소비 캠페인 시...
1000만원짜리 인공와우, 건강보험 지원 ‘평...
- - - - - - -
 

Nagasaki University Presented Results Of a Specified Clinical Trial On The Use of L. lactis strain Plasma For Patients With COVID-19

뉴스일자: 2023-05-14

TOKYO-- May 14, 2023 -- Nagasaki University presented the results of a specified clinical trial on patients with COVID-19 using Lactococcus. lactis strain Plasma[1](L.lactis Plasma, a postbiotic), researched and developed by Kirin Holdings Company, Limited (Kirin Holdings). The results of this research was presented at the 63rd Annual Scientific Meeting of the Japanese Respiratory Society on Sunday, April 30. Nagasaki University and Kirin Holdings have jointly filed a patent application for the findings of this specified clinical trial.

· Current status of COVID-19

Since December 2019, COVID-19 infections have repeatedly caused pandemics, infecting 676.57 million people worldwide and killing 6.88 million (as of March 10, 2023). With the emergence of Omicron variants, the number of cases in Japan has increased, and the COVID-19 has become a more familiar infectious disease. Although SARS-CoV-2 vaccines have introduced widely and patients with mild illnesses account for a large proportion of the affected population, only a limited number of drugs are available in patients with mild illnesses who are not at risk of developing severe illnesses, and treatment is mainly based on symptomatic therapy.[2] Therefore, there is eagerly awaited for an easily accessible, safe, and effective treatment for COVID-19 in the community.

· What is L. lactis strain Plasma?

L. lactis strain Plasma was discovered by Kirin in 2010 as a lactic acid bacteria that activates plasmacytoid dendritic cells (pDC), which are a leader of the immune system. Previous basic studies showed that L.lactis Plasma stimulated pDC to have a first-line defense to viral infectious diseases. Previous clinical studies have also shown that L.lactis Plasma stimulated pDC and suppress the onset of an illness from influenza virus, rotavirus, and dengue. These scientific evidence of its immune function brought L. lactis Plasma registered as the first[4] Food with Functional Claims in Japan on August 2020.

· Specified Clinical Research Contents

Based on the results of Kirin Holdings’ research on L. lactis Plasma, Nagasaki University, as a research institute with significant achievements in the field of infectious diseases, interested in L. lactis strain Plasma which may effect in relieving symptoms in patientis with COVID-19, and has decided to conduct a specified clinical trial from December 2021.

Since December 2021, Kirin Holdings has been engaged in a specific clinical research project led by Dr. Kazuko Yamamoto, a lecturer at the Department of Respiratory Medicine, Nagasaki University Hospital (currently a professor and chair at the Division of Infectious Diseases, Respiratory and Gastroenterological Medicine (First Department of Internal Medicine), University of the Ryukyus Graduate School of Medicine). This is a multicenter, double-blinded, randomized controlled trial conducted at Nagasaki University Hospital as a core facility. The efficacy and safety of 14 days oral intake of 4 hard capsules containing L. lactis Plasma (400 billion L. lactis Plasma in total) or 4 hard capsules without L. lactis Plasma (placebo) was to be evaluated[5] by having 50 patients with COVID-19 in each group.

· Specified Clinical Trial Results

1, Change in subjective symptom overall score (primary endpoint)

The results of an overall score analysis of seven subjective symptoms (Cough, Shortness of breath, fatigue, Headaches, Anosmia and Dysgeusia, Anorexia, and Chest pain) on a 4-point scale (0 points: not affected, 1 points: little effect, 2 points: affected, 3 points: severely affected) showed no difference between the two groups.

2, Anosmia and Dysgeusia (secondary endpoints) (Graph1)

The percentage of patients who scored 0 (not affected) for smell and taste dysfunction among subjective symptoms were high in the L. lactis strain Plasma group compared to placebo group after day 9.

3, Percent change in blood pDC (secondary endpoint) (Graph2)

While the placebo group showed a significant decrease in % pDC in the blood during COVID-19 clinical course, the L. lactis strain Plasma group maintained % pDC in the blood.

4, Percent change in SARS-CoV-2 viral load (secondary endpoint) (Graph3)

The L. lactis strain Plasma group showed a significant reduction of SARS-CoV-2 viral load at day 4 of treatment whereas placebo group showed reduction at day 8.

5, Safety and adverse events

No critical adverse events of safety were observed in this study.

Although this study did not show an effect on the primary endpoint, the subjective symptom total score, these results suggested that maintained pDC by the intake of L. lactis strain Plasma may have resulted in an early reduction of SARS-CoV-2 and early recovery of smell and taste dysfunction.

Nagasaki University and Kirin hope that L. lactis Plasma will become one of the new treatment or adjunctive care to patients with mild COVID-19.

[1] Lactococcus lactis subsp. lactis JCM 5805 is owned by the RIKEN BioResource Research Center (https://web.brc.riken.jp/en/)
[2] Approach to Pharmacotherapy for COVID-19 Version 15.1- the Japanese Association for Infectious Diseases
[3] Secrets of Immunity - Kirin's L. lactis strain Plasma Research https://health.kirin.co.jp/en/about/about.html
[4] The first brand in Japan to be registered with the Consumer Affairs Agency as a food with a functional claims for immune function.
[5] Yamamoto K, et al. BMJ Open 2022;12:e061172



 전체뉴스목록으로

MMCA×LG OLED Series Kicks Off to Bring Digital Art Closer to the Public
AppLogic Networks Secures Commitment from Leading MSP to Unlock New Revenue Paths with Edge-Ready, AI-Driven QoE Platform
SecurityBridge Acquires CyberSafe To Deliver Contextual SSO, MFA, And Passwordless Authentication To SAP Users
Kioxia Commences Sample Shipments of 9th Generation BiCS FLASHTM 512Gb TLC Devices
KnowBe4 Delivers AI-Driven Email Security to Small and Medium Businesses to Tackle Outbound Email Risk
Cisco Takes Licence to the Sisvel Wi-Fi 6 Patent Pool
HistoSonics’ Edison Histotripsy System Gains Great Britain Early Market Access Under Unmet Clinical Needs Authorisation

 

Omdia: Cloud Platforms Drive $12.9bn Games Market Ecosystem
Latest Mouser Series Navigates the Balance of AI and Human Expertise i...
DNP: Operational Launch of 2,500 mm-Width Coating Line to Enhance Prod...
ExaGrid Releases Version 7.3.0
MSCI Advances Private Markets Strategy With New Solutions Built for Ge...
Omdia: Asia’s Game Subscription Market Set to Reach $9.4bn by 2029
Experian Assistant Wins 2025 Globee Award for Technology

 


공지사항
뉴스지 한자 표기에 대만식 음차 표기 '纽斯集 니우시지' 병기
베네프롬 베네인투 중문 표기 宝乃福牧 宝乃因托(寶乃福牧 寶...
미디어아우어 Mediaour 媒体我们 媒體我們 MO 엠오 媒我 媒我
알리우브 Alliuv 阿备: 阿联有备, 알뜰 Althle 阿特益
알리알 Allial 중문 표기 阿利尔 阿利爾
뉴퍼스트 New1st 중문 표기 纽壹新(번체 紐壹新), N1 纽1
엔코스모스 : 이씨 'EnCosmos : EC' 중문 표기 以宙
아이디어론 Idearon 중문 표기 以迪论 以迪論
바이오이니 Bioini 중문 표기 必药研 必藥硏
오스프롬 Ausfrom 奥斯福牧, 웰프롬 Welfrom 卫福牧
에너프롬 Enerfrom 额能福牧 에너유비 Eneruv 额能有备
알프롬 Alfrom 중문 표기 阿尔福牧 阿爾福牧

 

회사소개 | 인재채용 | 이용약관 | 개인정보취급방침 | 청소년보호정책 | 책임한계와 법적고지 | 이메일주소무단수집거부 | 고객센터

기사제보 이메일 news@newsji.com, 전화 050 2222 0002, 팩스 050 2222 0111, 주소 : 서울 구로구 가마산로 27길 60 1-37호

인터넷뉴스서비스사업등록 : 서울 자00447, 등록일자 : 2013.12.23., 뉴스배열 및 청소년보호의 책임 : 대표 CEO

Copyright ⓒ All rights reserved..